These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 4037809

  • 1. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
    Takahashi K, Yokoyama M, Takahashi H, Wakui A.
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
    [Abstract] [Full Text] [Related]

  • 2. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
    Nishi I, Yokoyama T, Nakao I, Harashima S, Ohashi Y, Kanko T, Saito T.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
    [Abstract] [Full Text] [Related]

  • 3. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
    Meguro S, Nagata T, Yokoyama K, Chinen T, Kobayashi T, Yamazaki H, Kuraishi Y, Ichiba, Abe M, Isogai Y.
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
    [Abstract] [Full Text] [Related]

  • 4. [Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa].
    Shimizu E, Saijo N, Shinkai T, Eguchi K, Tominaga K, Nomori H, Sasaki Y, Garcia-Herreros P, Hoshi A.
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1290-5. PubMed ID: 6732255
    [Abstract] [Full Text] [Related]

  • 5. [Anticancer activities of a new mitomycin derivative KW 2149, against human tumors xenografted into nude mice].
    Nishiyama M, Kim R, Saeki T, Takagami S, Kirihara Y, Jinushi K, Toge T, Niimoto M, Hattori T.
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3133-7. PubMed ID: 3142368
    [Abstract] [Full Text] [Related]

  • 6. [Comparative study on the anticancer activities of KW2149 and mitomycin C against human tumor xenografts using subrenal capsule assay].
    Takagami S, Nishiyama M, Kim R, Kirihara Y, Jinushi K, Saeki K, Saeki T, Nosoh Y, Niimoto M, Hattori T.
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2189-93. PubMed ID: 2500067
    [Abstract] [Full Text] [Related]

  • 7. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
    Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Shibuya M, Shimabukuro Z.
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
    [Abstract] [Full Text] [Related]

  • 8. [Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1844-50. PubMed ID: 7184379
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
    Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H, Hoshi A.
    Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
    Fujita H.
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1362-73. PubMed ID: 6820913
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
    Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM.
    Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
    [Abstract] [Full Text] [Related]

  • 12. [A phase II study of SM-5887 for advanced gastric cancer].
    Tsushima K, Sakata Y, Munakata A, Sato T, Chiba Y, Nara H, Kawazu S, Matsukawa M, Ohmi T, Aizawa T.
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1151-4. PubMed ID: 1647150
    [Abstract] [Full Text] [Related]

  • 13. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
    Lee JH, Naito M, Tsuruo T.
    Cancer Res; 1994 May 01; 54(9):2398-403. PubMed ID: 8162587
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
    Meguro S, Nagata T, Yokoyama K, Chinen T, Yamazaki H, Kobayashi T, Isogai Y, Ogawa M.
    Invest New Drugs; 1984 May 01; 2(4):381-5. PubMed ID: 6511242
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
    Bradner WT, Rose WC, Schurig JE, Florczyk AP, Huftalen JB, Catino JJ.
    Cancer Res; 1985 Dec 01; 45(12 Pt 1):6475-81. PubMed ID: 3933826
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
    Tsuruo T, Sudo Y, Asami N, Inaba M, Morimoto M.
    Cancer Chemother Pharmacol; 1990 Dec 01; 27(2):89-93. PubMed ID: 2123421
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of mitomycin C in humans.
    den Hartigh J, McVie JG, van Oort WJ, Pinedo HM.
    Cancer Res; 1983 Oct 01; 43(10):5017-21. PubMed ID: 6411336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.